March 26th 2023
Between 2019 and 2020, there were 97 reported shortages among sponsor-reported antiseizure medications in Australia, 93% of which were generic brands.
High Incidence of Medication Errors Following Hospital Discharge Shown in Pediatric Epilepsy
March 3rd 2023Incidence of medication problems and their harm potential following hospital discharge among pediatric patients with epilepsy were not significantly different for individuals who received discharge medication education and those who did not.
Read More
Midazolam Nasal Spray Effective in Managing Seizure Clusters in Epilepsy
March 1st 2023Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with no recurrence seen from 10 minutes to 6 hours after the treatment.
Read More
Telementoring Program Linked With Improvement in Epilepsy Care Among School Nurses
February 22nd 2023School nurses reported improved knowledge and confidence in the care of students with seizures after undergoing the Project ECHO (Extension for Community Healthcare Outcomes) telementoring program for epilepsy.
Read More
Long-term Antidepressant Drug Use Linked With Risk of Epilepsy
February 11th 2023Individuals exposed to antidepressant drugs for longer than 365 days had an increased risk of epilepsy, particularly those given escitalopram, venlafaxine, and mirtazapine, according to a recent study conducted in Taiwan.
Read More
Dietary Therapies Show Short-term Effectiveness for Childhood Drug-Resistant Epilepsy
February 6th 2023The modified Atkins diet exhibited superior tolerability and effectiveness in reducing seizure frequency compared with other dietary therapies in the management of childhood drug-resistant epilepsy.
Read More
Epilepsy Incidence, Prevalence Greater in More Deprived UK Regions
February 1st 2023Significant geographical variation was found regarding the prevalence and incidence of epilepsy in United Kingdom primary care data between 2013 and 2018, suggesting a potential relationship between the disease and deprivation.
Read More
Valproate Exhibits Both Hypnotic, Antiepileptic Properties During Sleep
January 21st 2023In an animal study, researchers found that valproate, a common epilepsy drug, possessed hypnotic and antiepileptic properties during sleep, suggesting that the drug could help improve sleep quality for patients with nocturnal epilepsy.
Read More
Newer Drugs for Epilepsy Less Likely to Be Prescribed to Black, Latino Patients on Medicaid
January 11th 2023Patients with epilepsy on Medicaid insurance of Black, Latino, and Native Hawaiian and Other Pacific Island ethnicity were associated with lower odds of being on newer, second- and third-generation, antiseizure medications compared with White individuals.
Read More
In Pediatric Epilepsy, Links Found Between Parental Factors, Emotional and Behavioral Issues
January 10th 2023A study showed 18.3% of adolescents with epilepsy (AWE) had at least 1 emotional or behavioral problem, and 24.9% of parents felt others had stigma towards their children with epilepsy.
Read More
Developing a Framework to Address Health Inequities in Epilepsy
January 6th 2023A review explored the connection between 4 domains (structural, sociocultural, health care, and physiological) contributing to the persistence of inequities in epilepsy risk and outcomes in the United States, as well as key areas of intervention to promote health equity.
Read More
Raising the Overall Awareness for Infantile Spasms, Early Recognition of Pre-Epilepsy Diagnosis
December 22nd 2022Martina Bebin, MD, MPA, professor of neurology, University of Alabama at Birmingham Epilepsy Center, discussed Infantile Spasms Awareness Week, the strides made within the field, and the emphasis on early and accurate diagnosis.
Read More
Telemedicine Care Quality, Social Vulnerability Index Barriers Measured for Patients With Epilepsy
December 12th 2022Abstracts from the American Epilepsy Society annual meeting show that telemedicine is capable of meeting the needs of patients with epilepsy, and that the patient portal accessibility for patients experiencing high social vulnerability index needs further research.
Read More
Two Pediatric Tertiary Care Centers Evaluate Efficacy of CBD on Refractory, Intractable Epilepsy
December 9th 2022Abstracts from the American Epilepsy Society (AES) display potential benefits of cannabidiol (CBD) on pediatric patients with epilepsy in tertiary care centers and highlight areas where further research is needed.
Read More
CBD May Improve Neurologic, Cognitive, QOL Outcomes in Sturge-Weber Syndrome
November 28th 2022A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.
Read More
What We’re Reading: Epilepsy Drug Approval; Free COVID-19 Testing Ends; EPA Sued
March 28th 2022The FDA approved a drug to treat a rare form of childhood epilepsy; uninsured Americans will no longer have access to free COVID-19 tests; a conservation group is suing the Environmental Protection Agency (EPA) over failure to protect rivers from pollution.
Read More
Poor Sleep Quality, Care Management Linked With Worsening of Seizure in Patients With Epilepsy
July 28th 2020Amid the coronavirus disease 2019 pandemic in Italy, a significant number of patients with epilepsy reported difficulties managing their condition, especially those who reported greater use of antiseizure medications for chronic therapy and poor sleep quality, according to study findings.
Read More